Glucagon-Like Peptide Receptor Agonists

Abstract

Get full access to this article

View all access options for this article.

References

National Diabetes Report 2014. Centers for Disease Control and Prevention. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed July 23, 2014.

Fineman

Cirincione

Maggs

Diamant

. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab. 2012;14:675-688.

Lilly announces detailed results from two phase III studies testing both doses of dulaglutide vs. insulin glargine. drugs.com http://www.drugs.com/clinical_trials/lilly-announces-detailed-results-two-phase-iii-studies-testing-both-doses-dulaglutide-vs-insulin-16576.html. Accessed August 3, 2014.

Jendle

Rosenstock

. Better glycemic control and less weight gain with once-weekly dulaglutide vs. once-daily insulin glargine, both combined with premeal insulin lispro, in type 2 diabetes patients (AWARD-4). Abstract 962-P. Presented at 74th American Diabetes Association (ADA) Scientific Sessions, June 13-17, 2014, San Francisco, CA.